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Post-Myocardial Infarction Cardiogenic Shock
Is a Systemic Illness in Need of Systemic Treatment
Is Therapeutic Hypothermia One Possibility?
Brian M. Stegman, MD,* L. Kristin Newby, MD, MHS,† Judith S. Hochman, MD,‡
E. Magnus Ohman, MD†
Durham, North Carolina; and New York, New York
Early observations of cardiogenic shock as a systemic clinical syndrome were first described in 1942. Today,
cardiogenic shock remains the leading cause of death among patients hospitalized for myocardial infarction
(MI). Mortality rates in post-MI cardiogenic shock approach 50% despite rapid revascularization, optimal medical
care, and use of mechanical support. New therapeutic strategies with global systemic effects may offer ad-
vances in treatment and outcome in post-MI cardiogenic shock. Therapeutic hypothermia for post-MI cardiogenic
shock has multiple potentially beneficial physiologic effects, including the potential to improve post-ischemic
cardiac function and hemodynamics, decrease myocardial damage, and reduce end-organ injury from prolonged
hypoperfusion. Available data in animal models of post-MI cardiogenic shock and ischemia/reperfusion injury
and small case series of human patients with cardiogenic shock suggest its promise as a potential therapeutic
strategy for cardiogenic shock in the post-MI setting. We hypothesize that systemic therapeutic hypothermia
could decrease morbidity and mortality in post-MI patients with cardiogenic shock and warrants study a
new treatment that could be widely available at hospitals worldwide. (J Am Coll Cardiol 2012;59:644–7)
© 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.11.010In 1942, Stead and Ebert published their seminal observa-
tions of the manifestations of shock resulting from failure of
the heart, “characterized clinically by the signs of a marked
decrease in cardiac output and tissue anoxia. . .,” as a disease
with broad-ranging systemic effects (1). Today, nearly 70
years later, cardiogenic shock remains the major killer of
patients hospitalized for acute myocardial infarction (MI),
with mortality approaching 50% despite urgent reperfusion
therapy, optimal medical care, and intra-aortic balloon
pumping (2).
Cardiogenic shock is generally defined by cardiac index
2.2 l/min/m2, hypotension, elevated pulmonary capillary
wedge pressure, and end-organ hypoperfusion. Cardiogenic
shock affects approximately 5% to 7% of patients with MI
and is the leading cause of death among hospitalized
patients with MI (2). Unfortunately, there have been few
recent advances in the treatment of cardiogenic shock in the
setting of MI. A small study of advanced mechanical
support using left ventricular (LV) assist devices revealed
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benefit from use of such devices in the setting of acute MI
has not been demonstrated (3). These mechanical treat-
ments also require highly specialized care at large medical
centers, which could significantly limit availability to many
patients with acute MI with cardiogenic shock who are
initially treated in community centers. Therapeutic hypo-
thermia is widely available and has become a standard
component of treatment for out-of-hospital ventricular
tachycardia/ventricular fibrillation arrest (4). It also has
wide-ranging systemic effects that might be particularly
advantageous when considering the systemic manifestations
of cardiogenic shock in the post-MI setting. We hypothe-
sized the following: first, the properties of therapeutic
hypothermia that protect the brain and promote recovery
after cardiac arrest will have similar effects on other vital
organs; and second, therapeutic hypothermia merits further
study as a potential novel treatment for post-MI cardiogenic
shock and could represent the next measurable advance in
survival after MI.
Animal Models, Molecular Profiles,
and Early Human Studies of Hypothermia
Hypoperfusion in the setting of post-MI cardiogenic shock
leads to multiple end-organ damage and dysfunction that
contributes to morbidity and mortality after MI. Hypothermia
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body temperature, and it decreases oxygen consumption,
carbon dioxide production, and glucose consumption (5). In
addition, hypothermia affects the cardiovascular system in
multiple ways, many of which could be potentially beneficial
in cardiogenic shock, especially in a post-MI setting. In
dogs, reduction of body temperature to 34°C in conjunction
with vasodilator therapy results in increased contractility
and external work of the left ventricle without increasing
myocardial oxygen consumption (6). In a dog model of
post-MI cardiogenic shock, treatment with hypothermia to
32°C reduced heart rate, LV end-diastolic pressure, sys-
temic oxygen consumption, and estimated myocardial oxy-
gen consumption while maintaining cardiac output and
improving survival (7). This study was validated recently in
a porcine model of post-MI cardiogenic shock showing that
animals treated with hypothermia had increased mean
arterial pressure, stroke volume, pH, and mixed venous
oxygen saturation with decreased heart rate (8). Mortality
was also improved in the hypothermia group (0% mortality in
the hypothermia group vs. 63% in the control group). The
inotropic effects of hypothermia seem to be at least partially
related to an increase in action potential duration, calcium
transients, sarcoplasmic reticulum calcium stores, and the
fractional release of calcium in individual cardiac myocytes (9).
Results of animal models further suggest that therapeutic
ypothermia may reduce ischemia/reperfusion injury after
rgent revascularization for acute MI. In dogs, hypothermia
eginning 30 min after left anterior descending coronary
rtery occlusion and continued through reperfusion 3 hours
ater improved cardiac function during occlusion, blunted
emodynamic derangements during reperfusion, and re-
uced infarct size at 7 days (10). In sheep, in addition to
reater immediate myocardial salvage, LV systolic function
as improved at 8 weeks in animals treated with therapeutic
ypothermia (11). One study in humans showed decreased
nfarct size among patients with anterior infarcts treated
ith therapeutic hypothermia who reached a temperature of
35°C at time of reperfusion (12). More recently, a pilot
tudy of 20 patients with acute MI undergoing endovascular
ooling and cold saline infusion to ensure body temperature
f 35°C at time of reperfusion demonstrated a significant
ecrease in infarct size and biomarker elevation without
ncreasing door-to-balloon time (13). To the best of our
nowledge, there have been no randomized human studies
f therapeutic hypothermia in post-MI cardiogenic shock.
Hypothermia has additional outcomes outside its direct
ardiovascular effects that may benefit patients with
ost-MI cardiogenic shock. Accumulation of oxygen free
adicals and an intense inflammatory response are hallmarks
f myocardial ischemia and systemic hypoperfusion in
ost-MI cardiogenic shock (14,15). Hypothermia impairs
eutrophil and macrophage phagocytic function and pro-
uction of many proinflammatory cytokines (5). Therefore,
herapeutic hypothermia could decrease the severity of
yocardial injury and dysfunction associated with MI. aurthermore, hypothermia at-
enuates ischemia/reperfusion
njury in other organ systems and
educes endothelial cell apoptosis
nd systemic oxidative stress
16,17). Hypothermia also in-
reases urine output, likely via reduction in fluid resorption
eyond the mid-distal tubule in the kidney (18), an effect
hat could prove beneficial in post-MI cardiogenic shock
atients with difficult-to-manage volume status. Figure 1
dentifies potential pathways leading to or mediating the
ystemic effects of cardiogenic shock and where preclinical
ata suggest therapeutic hypothermia may modulate these
ffects.
uman Studies of
ypothermia in Cardiogenic Shock
here are only a few case reports and case series of
ypothermia in patients with cardiogenic shock, mostly
imited to pediatric and adult cardiac surgery patients whose
ostoperative courses were complicated by cardiogenic
hock (19–21); none were from patients with cardiogenic
hock in the acute MI setting. It is also important to
ecognize that these are reports of highly selected cases in
hich treatment was nonrandomized and concurrent ther-
py was uncontrolled. Only a well-designed randomized
linical trial can provide evidence sufficient to support
linical practice in post-MI patients. In general, whether in
nfants or children, when hypothermia is added to conven-
ional therapy in patients with refractory shock after cardio-
horacic surgery, it resulted in decreases in heart rate and
ncreases in mean arterial pressure and urine output with
mproved clinical stability (19,20). Therapeutic hypother-
ia has been reported in only one case series in adult
atients with refractory heart failure (21). In this report, 10
dult patients experienced post–cardiac surgery cardiogenic
hock that was refractory to medical therapy, including
ultiple vasopressors and intra-aortic balloon pumping; the
se of external cooling along with cold gastric lavage to a
emperature of 34.5°C resulted in improved cardiac index
1.9 0.3 to 2.2 0.3), mixed venous saturation (55 7%
o 64  6%), and urine output (2.1  1.1 ml/kg/h to 3.4 
.2 ml/kg/h) without changes in mean arterial pressure,
eart rate, systemic vascular resistance, or pH. Eight of 10
atients survived to discharge.
Patients with signs of cardiogenic shock after cardiac
rrest who underwent cooling provide another possible
ource of information, although little is currently available.
n one study, 28 of 56 patients who were cooled after cardiac
rrest also had cardiogenic shock, although it was not
eported how many of these patients had acute MI concur-
ent with the cardiac arrest (22). Among the cardiogenic
hock patients, after 24 to 48 h of therapeutic hypothermia,
ardiac index increased from 1.5  0.26 to 2.3  0.371. In
Abbreviation and
Acronym
LV  left ventricular
MI  myocardial infarctionddition, heart rate decreased among cardiogenic shock
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shock; mean arterial pressure increased in patients with cardio-
genic shock whereas it decreased in patients without initial
signs of shock.
Potentially Detrimental
Effects of Therapeutic Hypothermia
Induction of hypothermia has been associated with altera-
tions in normal physiology that could prove detrimental and
may create challenges for future clinical trials of therapeutic
hypothermia in post-MI cardiogenic shock. For example,
therapeutic cooling to core temperatures of 32°C to 34°C
results in shivering, which is both uncomfortable for the
patient and increases systemic oxygen consumption (5).
Shivering is best controlled with sedation and paralysis
during cooling that necessitates intubation and mechanical
ventilation. In general practice, 85% of patients with car-
diogenic shock in the setting of acute MI require mechan-
ical ventilation during their treatment, but the risks of such
treatment in the patients who otherwise would not have
required it must be explored (23). Furthermore, hypother-
mia reportedly increases the risk of infection (especially
pneumonia), coagulopathy, electrolyte abnormalities, and
arrhythmias, although these risks have not translated to
worsened clinical outcomes in cardiac arrest patients (5,24).
These potential adverse effects must also be understood in
balance with potential benefits in the post-MI cardiogenic
Figure 1 Pathways Potentially Affected by Therapeutic Hypoth
Graphic summarizes ways in which therapeutic hypothermia may block certain pat
CO  cardiac output; LVEDP  left ventricular end-diastolic pressure; NO  nitricshock setting.Conclusions
Rapid reperfusion to treat coronary obstruction is a major
advance in treating patients with acute MI presenting with
cardiogenic shock. Unfortunately, mortality remains high in
patients who have cardiogenic shock that persists after
reperfusion. Now, 70 years after the seminal description of
the systemic manifestations of cardiogenic shock, it is time
to draw on those observations to direct development of new
approaches that address the systemic consequences of
post-MI cardiogenic shock and protect end organs during
stabilization. Therapeutic hypothermia has many physio-
logic effects that could be beneficial to patients with
post-MI shock. Among these, the potential to improve
cardiac function and hemodynamics and reduce end-organ
damage from prolonged hypoperfusion may be the most
relevant. Favorable effects of therapeutic hypothermia have
been demonstrated in animal studies and small case series of
patients with non-MI cardiogenic shock. Therefore, thera-
peutic hypothermia warrants further investigation as a
potential treatment strategy for post-MI cardiogenic shock
to address the multitude of clinical effects that characterize
the downward spiral that so frequently defines this fatal
complication of MI.
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